CREB-binding protein (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "CREB-binding protein" in English language version.

refsWebsite

Global rank English rank

58nih.gov

4^th place

37doi.org

2^nd place

11semanticscholar.org

11^th place

8^th place

2ensembl.org

1,626^th place

1,007^th place

2worldcat.org

5^th place

2harvard.edu

18^th place

17^th place

1ashpublications.org

low place

1eisai.com

low place

ashpublications.org

Blobel GA (2000-02-01). "CREB-binding protein and p300: molecular integrators of hematopoietic transcription". Blood. 95 (3): 745–755. doi:10.1182/blood.V95.3.745.003k05_745_755. ISSN 1528-0020. PMID 10648382.

doi.org

Chan HM, La Thangue NB (July 2001). "p300/CBP proteins: HATs for transcriptional bridges and scaffolds". Journal of Cell Science. 114 (Pt 13): 2363–2373. doi:10.1242/jcs.114.13.2363. PMID 11559745.
Yao W, Wang T, Huang F (2018). "p300/CBP as a Key Nutritional Sensor for Hepatic Energy Homeostasis and Liver Fibrosis". BioMed Research International. 2018: 8168791. doi:10.1155/2018/8168791. PMC 5976926. PMID 29862292.
Vo N, Goodman RH (April 2001). "CREB-binding protein and p300 in transcriptional regulation". The Journal of Biological Chemistry. 276 (17): 13505–13508. doi:10.1074/jbc.R000025200. PMID 11279224.
Akinsiku OE, Soremekun OS, Soliman ME (February 2021). "Update and Potential Opportunities in CBP [Cyclic Adenosine Monophosphate (cAMP) Response Element-Binding Protein (CREB)-Binding Protein] Research Using Computational Techniques". The Protein Journal. 40 (1): 19–27. doi:10.1007/s10930-020-09951-8. PMC 7868315. PMID 33394237.
Guo P, Chen W, Li H, Li M, Li L (October 2018). "The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications". Pathology & Oncology Research. 24 (4): 807–813. doi:10.1007/s12253-018-0433-5. PMID 29948617. S2CID 47020435.
He ZX, Wei BF, Zhang X, Gong YP, Ma LY, Zhao W (January 2021). "Current development of CBP/p300 inhibitors in the last decade". European Journal of Medicinal Chemistry. 209: 112861. doi:10.1016/j.ejmech.2020.112861. ISSN 0223-5234. PMID 33045661. S2CID 222319204.
Bordonaro M, Lazarova DL (July 2015). "CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer". World Journal of Gastroenterology. 21 (27): 8238–8248. doi:10.3748/wjg.v21.i27.8238. PMC 4507093. PMID 26217075.
Attar N, Kurdistani SK (March 2017). "Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer". Cold Spring Harbor Perspectives in Medicine. 7 (3): a026534. doi:10.1101/cshperspect.a026534. PMC 5334244. PMID 27881443.
Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, et al. (July 2018). "Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer". Genome Medicine. 10 (1): 54. doi:10.1186/s13073-018-0569-7. PMC 6053793. PMID 30029671.
Rouaux C, Loeffler JP, Boutillier AL (September 2004). "Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders". Biochemical Pharmacology. 68 (6): 1157–1164. doi:10.1016/j.bcp.2004.05.035. PMID 15313413.
Wang H, Xu J, Lazarovici P, Quirion R, Zheng W (2018-08-30). "cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia". Frontiers in Molecular Neuroscience. 11: 255. doi:10.3389/fnmol.2018.00255. PMC 6125665. PMID 30214393.
Amidfar M, de Oliveira J, Kucharska E, Budni J, Kim YK (September 2020). "The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease". Life Sciences. 257: 118020. doi:10.1016/j.lfs.2020.118020. PMID 32603820. S2CID 220287306.
Steven A, Friedrich M, Jank P, Heimer N, Budczies J, Denkert C, Seliger B (October 2020). "What turns CREB on? And off? And why does it matter?". Cellular and Molecular Life Sciences. 77 (20): 4049–4067. doi:10.1007/s00018-020-03525-8. PMC 7532970. PMID 32347317.
Dutta R, Tiu B, Sakamoto KM (September 2016). "CBP/p300 acetyltransferase activity in hematologic malignancies". Molecular Genetics and Metabolism. 119 (1–2): 37–43. doi:10.1016/j.ymgme.2016.06.013. PMID 27380996.
Dyson HJ, Wright PE (March 2016). "Role of Intrinsic Protein Disorder in the Function and Interactions of the Transcriptional Coactivators CREB-binding Protein (CBP) and p300". The Journal of Biological Chemistry. 291 (13): 6714–6722. doi:10.1074/jbc.R115.692020. PMC 4807259. PMID 26851278.
Sapio L, Salzillo A, Ragone A, Illiano M, Spina A, Naviglio S (October 2020). "Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update". Cancers. 12 (11): 3166. doi:10.3390/cancers12113166. PMC 7693618. PMID 33126560.
Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG (April 2007). "Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis". Cell Research. 17 (4): 324–332. doi:10.1038/cr.2007.10. PMID 17372613. S2CID 36084602.
Valor LM, Viosca J, Lopez-Atalaya JP, Barco A (2013-07-31). "Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders". Current Pharmaceutical Design. 19 (28): 5051–5064. doi:10.2174/13816128113199990382. PMC 3722569. PMID 23448461.
Dutto I, Scalera C, Prosperi E (April 2018). "CREBBP and p300 lysine acetyl transferases in the DNA damage response". Cellular and Molecular Life Sciences. 75 (8): 1325–1338. doi:10.1007/s00018-017-2717-4. PMC 11105205. PMID 29170789. S2CID 3951961.
Mullan PB, Quinn JE, Harkin DP (September 2006). "The role of BRCA1 in transcriptional regulation and cell cycle control". Oncogene. 25 (43): 5854–5863. doi:10.1038/sj.onc.1209872. PMID 16998500. S2CID 41157893.
Blobel GA (2000-02-01). "CREB-binding protein and p300: molecular integrators of hematopoietic transcription". Blood. 95 (3): 745–755. doi:10.1182/blood.V95.3.745.003k05_745_755. ISSN 1528-0020. PMID 10648382.
Newton AL, Sharpe BK, Kwan A, Mackay JP, Crossley M (May 2000). "The transactivation domain within cysteine/histidine-rich region 1 of CBP comprises two novel zinc-binding modules". The Journal of Biological Chemistry. 275 (20): 15128–15134. doi:10.1074/jbc.M910396199. PMID 10748221.
Cantor AB, Orkin SH (May 2002). "Transcriptional regulation of erythropoiesis: an affair involving multiple partners". Oncogene. 21 (21): 3368–3376. doi:10.1038/sj.onc.1205326. PMID 12032775. S2CID 33364155.
Siddique H, Rao VN, Reddy ES (August 2009). "CBP-mediated post-translational N-glycosylation of BRCA2". International Journal of Oncology. 35 (2): 387–391. doi:10.3892/ijo_00000351. PMID 19578754.
Ait-Si-Ali S, Ramirez S, Barre FX, Dkhissi F, Magnaghi-Jaulin L, Girault JA, et al. (November 1998). "Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A". Nature. 396 (6707): 184–186. Bibcode:1998Natur.396..184A. doi:10.1038/24190. PMID 9823900. S2CID 4340781.
Zhang H, Kong Q, Wang J, Jiang Y, Hua H (November 2020). "Complex roles of cAMP-PKA-CREB signaling in cancer". Experimental Hematology & Oncology. 9 (1): 32. doi:10.1186/s40164-020-00191-1. PMC 7684908. PMID 33292604.
Rubin SM, Sage J, Skotheim JM (October 2020). "Integrating Old and New Paradigms of G1/S Control". Molecular Cell. 80 (2): 183–192. doi:10.1016/j.molcel.2020.08.020. PMC 7582788. PMID 32946743.
Bodrug T, Welsh KA, Hinkle M, Emanuele MJ, Brown NG (2021-05-24). "Intricate Regulatory Mechanisms of the Anaphase-Promoting Complex/Cyclosome and Its Role in Chromatin Regulation". Frontiers in Cell and Developmental Biology. 9: 687515. doi:10.3389/fcell.2021.687515. PMC 8182066. PMID 34109183.
Turnell AS, Stewart GS, Grand RJ, Rookes SM, Martin A, Yamano H, et al. (December 2005). "The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression". Nature. 438 (7068): 690–695. Bibcode:2005Natur.438..690T. doi:10.1038/nature04151. PMID 16319895. S2CID 4432156.
Van Gils J, Magdinier F, Fergelot P, Lacombe D (June 2021). "Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder". Genes. 12 (7): 968. doi:10.3390/genes12070968. PMC 8303114. PMID 34202860.
Kim C, Yousefian-Jazi A, Choi SH, Chang I, Lee J, Ryu H (November 2021). "Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease". International Journal of Molecular Sciences. 22 (22): 12499. doi:10.3390/ijms222212499. PMC 8617801. PMID 34830381.
Wang Y, Xie Q, Tan H, Liao M, Zhu S, Zheng LL, et al. (November 2021). "Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies". Pharmacological Research. 173: 105702. doi:10.1016/j.phrs.2021.105702. PMID 34102228. S2CID 235378858.
Akinsiku OE, Soremekun OS, Olotu FA, Soliman ME (2020). "Exploring the Role of Asp1116 in Selective Drug Targeting of CREBcAMP- Responsive Element-binding Protein Implicated in Prostate Cancer". Combinatorial Chemistry & High Throughput Screening. 23 (3): 178–184. doi:10.2174/1386207323666200219122057. PMID 32072894. S2CID 211193693.
Waddell AR, Huang H, Liao D (June 2021). "CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers". Cancers. 13 (12): 2872. doi:10.3390/cancers13122872. PMC 8229436. PMID 34201346.
Romero FA, Murray J, Lai KW, Tsui V, Albrecht BK, An L, et al. (November 2017). "GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)". Journal of Medicinal Chemistry. 60 (22): 9162–9183. doi:10.1021/acs.jmedchem.7b00796. PMID 28892380.
Farria A, Li W, Dent SY (September 2015). "KATs in cancer: functions and therapies". Oncogene. 34 (38): 4901–4913. doi:10.1038/onc.2014.453. PMC 4530097. PMID 25659580.
Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, et al. (December 2012). "Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP". Clinical Cancer Research. 18 (24): 6623–6633. doi:10.1158/1078-0432.CCR-12-0861. PMC 3518680. PMID 22923450.

eisai.com

"The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept) | News Release：2021 | Eisai Co., Ltd". www.eisai.com. Retrieved 2021-12-04.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000005339 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000022521 – Ensembl, May 2017

harvard.edu

ui.adsabs.harvard.edu

Ait-Si-Ali S, Ramirez S, Barre FX, Dkhissi F, Magnaghi-Jaulin L, Girault JA, et al. (November 1998). "Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A". Nature. 396 (6707): 184–186. Bibcode:1998Natur.396..184A. doi:10.1038/24190. PMID 9823900. S2CID 4340781.
Turnell AS, Stewart GS, Grand RJ, Rookes SM, Martin A, Yamano H, et al. (December 2005). "The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression". Nature. 438 (7068): 690–695. Bibcode:2005Natur.438..690T. doi:10.1038/nature04151. PMID 16319895. S2CID 4432156.

nih.gov

pubmed.ncbi.nlm.nih.gov

Chan HM, La Thangue NB (July 2001). "p300/CBP proteins: HATs for transcriptional bridges and scaffolds". Journal of Cell Science. 114 (Pt 13): 2363–2373. doi:10.1242/jcs.114.13.2363. PMID 11559745.
Yao W, Wang T, Huang F (2018). "p300/CBP as a Key Nutritional Sensor for Hepatic Energy Homeostasis and Liver Fibrosis". BioMed Research International. 2018: 8168791. doi:10.1155/2018/8168791. PMC 5976926. PMID 29862292.
Vo N, Goodman RH (April 2001). "CREB-binding protein and p300 in transcriptional regulation". The Journal of Biological Chemistry. 276 (17): 13505–13508. doi:10.1074/jbc.R000025200. PMID 11279224.
Akinsiku OE, Soremekun OS, Soliman ME (February 2021). "Update and Potential Opportunities in CBP [Cyclic Adenosine Monophosphate (cAMP) Response Element-Binding Protein (CREB)-Binding Protein] Research Using Computational Techniques". The Protein Journal. 40 (1): 19–27. doi:10.1007/s10930-020-09951-8. PMC 7868315. PMID 33394237.
Guo P, Chen W, Li H, Li M, Li L (October 2018). "The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications". Pathology & Oncology Research. 24 (4): 807–813. doi:10.1007/s12253-018-0433-5. PMID 29948617. S2CID 47020435.
He ZX, Wei BF, Zhang X, Gong YP, Ma LY, Zhao W (January 2021). "Current development of CBP/p300 inhibitors in the last decade". European Journal of Medicinal Chemistry. 209: 112861. doi:10.1016/j.ejmech.2020.112861. ISSN 0223-5234. PMID 33045661. S2CID 222319204.
Bordonaro M, Lazarova DL (July 2015). "CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer". World Journal of Gastroenterology. 21 (27): 8238–8248. doi:10.3748/wjg.v21.i27.8238. PMC 4507093. PMID 26217075.
Attar N, Kurdistani SK (March 2017). "Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer". Cold Spring Harbor Perspectives in Medicine. 7 (3): a026534. doi:10.1101/cshperspect.a026534. PMC 5334244. PMID 27881443.
Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, et al. (July 2018). "Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer". Genome Medicine. 10 (1): 54. doi:10.1186/s13073-018-0569-7. PMC 6053793. PMID 30029671.
Rouaux C, Loeffler JP, Boutillier AL (September 2004). "Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders". Biochemical Pharmacology. 68 (6): 1157–1164. doi:10.1016/j.bcp.2004.05.035. PMID 15313413.
Wang H, Xu J, Lazarovici P, Quirion R, Zheng W (2018-08-30). "cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia". Frontiers in Molecular Neuroscience. 11: 255. doi:10.3389/fnmol.2018.00255. PMC 6125665. PMID 30214393.
Amidfar M, de Oliveira J, Kucharska E, Budni J, Kim YK (September 2020). "The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease". Life Sciences. 257: 118020. doi:10.1016/j.lfs.2020.118020. PMID 32603820. S2CID 220287306.
Steven A, Friedrich M, Jank P, Heimer N, Budczies J, Denkert C, Seliger B (October 2020). "What turns CREB on? And off? And why does it matter?". Cellular and Molecular Life Sciences. 77 (20): 4049–4067. doi:10.1007/s00018-020-03525-8. PMC 7532970. PMID 32347317.
Dutta R, Tiu B, Sakamoto KM (September 2016). "CBP/p300 acetyltransferase activity in hematologic malignancies". Molecular Genetics and Metabolism. 119 (1–2): 37–43. doi:10.1016/j.ymgme.2016.06.013. PMID 27380996.
Dyson HJ, Wright PE (March 2016). "Role of Intrinsic Protein Disorder in the Function and Interactions of the Transcriptional Coactivators CREB-binding Protein (CBP) and p300". The Journal of Biological Chemistry. 291 (13): 6714–6722. doi:10.1074/jbc.R115.692020. PMC 4807259. PMID 26851278.
Sapio L, Salzillo A, Ragone A, Illiano M, Spina A, Naviglio S (October 2020). "Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update". Cancers. 12 (11): 3166. doi:10.3390/cancers12113166. PMC 7693618. PMID 33126560.
Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG (April 2007). "Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis". Cell Research. 17 (4): 324–332. doi:10.1038/cr.2007.10. PMID 17372613. S2CID 36084602.
Valor LM, Viosca J, Lopez-Atalaya JP, Barco A (2013-07-31). "Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders". Current Pharmaceutical Design. 19 (28): 5051–5064. doi:10.2174/13816128113199990382. PMC 3722569. PMID 23448461.
Dutto I, Scalera C, Prosperi E (April 2018). "CREBBP and p300 lysine acetyl transferases in the DNA damage response". Cellular and Molecular Life Sciences. 75 (8): 1325–1338. doi:10.1007/s00018-017-2717-4. PMC 11105205. PMID 29170789. S2CID 3951961.
Mullan PB, Quinn JE, Harkin DP (September 2006). "The role of BRCA1 in transcriptional regulation and cell cycle control". Oncogene. 25 (43): 5854–5863. doi:10.1038/sj.onc.1209872. PMID 16998500. S2CID 41157893.
Blobel GA (2000-02-01). "CREB-binding protein and p300: molecular integrators of hematopoietic transcription". Blood. 95 (3): 745–755. doi:10.1182/blood.V95.3.745.003k05_745_755. ISSN 1528-0020. PMID 10648382.
Newton AL, Sharpe BK, Kwan A, Mackay JP, Crossley M (May 2000). "The transactivation domain within cysteine/histidine-rich region 1 of CBP comprises two novel zinc-binding modules". The Journal of Biological Chemistry. 275 (20): 15128–15134. doi:10.1074/jbc.M910396199. PMID 10748221.
Cantor AB, Orkin SH (May 2002). "Transcriptional regulation of erythropoiesis: an affair involving multiple partners". Oncogene. 21 (21): 3368–3376. doi:10.1038/sj.onc.1205326. PMID 12032775. S2CID 33364155.
Siddique H, Rao VN, Reddy ES (August 2009). "CBP-mediated post-translational N-glycosylation of BRCA2". International Journal of Oncology. 35 (2): 387–391. doi:10.3892/ijo_00000351. PMID 19578754.
Ait-Si-Ali S, Ramirez S, Barre FX, Dkhissi F, Magnaghi-Jaulin L, Girault JA, et al. (November 1998). "Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A". Nature. 396 (6707): 184–186. Bibcode:1998Natur.396..184A. doi:10.1038/24190. PMID 9823900. S2CID 4340781.
Zhang H, Kong Q, Wang J, Jiang Y, Hua H (November 2020). "Complex roles of cAMP-PKA-CREB signaling in cancer". Experimental Hematology & Oncology. 9 (1): 32. doi:10.1186/s40164-020-00191-1. PMC 7684908. PMID 33292604.
Rubin SM, Sage J, Skotheim JM (October 2020). "Integrating Old and New Paradigms of G1/S Control". Molecular Cell. 80 (2): 183–192. doi:10.1016/j.molcel.2020.08.020. PMC 7582788. PMID 32946743.
Bodrug T, Welsh KA, Hinkle M, Emanuele MJ, Brown NG (2021-05-24). "Intricate Regulatory Mechanisms of the Anaphase-Promoting Complex/Cyclosome and Its Role in Chromatin Regulation". Frontiers in Cell and Developmental Biology. 9: 687515. doi:10.3389/fcell.2021.687515. PMC 8182066. PMID 34109183.
Turnell AS, Stewart GS, Grand RJ, Rookes SM, Martin A, Yamano H, et al. (December 2005). "The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression". Nature. 438 (7068): 690–695. Bibcode:2005Natur.438..690T. doi:10.1038/nature04151. PMID 16319895. S2CID 4432156.
Van Gils J, Magdinier F, Fergelot P, Lacombe D (June 2021). "Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder". Genes. 12 (7): 968. doi:10.3390/genes12070968. PMC 8303114. PMID 34202860.
Kim C, Yousefian-Jazi A, Choi SH, Chang I, Lee J, Ryu H (November 2021). "Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease". International Journal of Molecular Sciences. 22 (22): 12499. doi:10.3390/ijms222212499. PMC 8617801. PMID 34830381.
Wang Y, Xie Q, Tan H, Liao M, Zhu S, Zheng LL, et al. (November 2021). "Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies". Pharmacological Research. 173: 105702. doi:10.1016/j.phrs.2021.105702. PMID 34102228. S2CID 235378858.
Akinsiku OE, Soremekun OS, Olotu FA, Soliman ME (2020). "Exploring the Role of Asp1116 in Selective Drug Targeting of CREBcAMP- Responsive Element-binding Protein Implicated in Prostate Cancer". Combinatorial Chemistry & High Throughput Screening. 23 (3): 178–184. doi:10.2174/1386207323666200219122057. PMID 32072894. S2CID 211193693.
Waddell AR, Huang H, Liao D (June 2021). "CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers". Cancers. 13 (12): 2872. doi:10.3390/cancers13122872. PMC 8229436. PMID 34201346.
Romero FA, Murray J, Lai KW, Tsui V, Albrecht BK, An L, et al. (November 2017). "GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)". Journal of Medicinal Chemistry. 60 (22): 9162–9183. doi:10.1021/acs.jmedchem.7b00796. PMID 28892380.
Farria A, Li W, Dent SY (September 2015). "KATs in cancer: functions and therapies". Oncogene. 34 (38): 4901–4913. doi:10.1038/onc.2014.453. PMC 4530097. PMID 25659580.
Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, et al. (December 2012). "Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP". Clinical Cancer Research. 18 (24): 6623–6633. doi:10.1158/1078-0432.CCR-12-0861. PMC 3518680. PMID 22923450.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Yao W, Wang T, Huang F (2018). "p300/CBP as a Key Nutritional Sensor for Hepatic Energy Homeostasis and Liver Fibrosis". BioMed Research International. 2018: 8168791. doi:10.1155/2018/8168791. PMC 5976926. PMID 29862292.
Akinsiku OE, Soremekun OS, Soliman ME (February 2021). "Update and Potential Opportunities in CBP [Cyclic Adenosine Monophosphate (cAMP) Response Element-Binding Protein (CREB)-Binding Protein] Research Using Computational Techniques". The Protein Journal. 40 (1): 19–27. doi:10.1007/s10930-020-09951-8. PMC 7868315. PMID 33394237.
Bordonaro M, Lazarova DL (July 2015). "CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer". World Journal of Gastroenterology. 21 (27): 8238–8248. doi:10.3748/wjg.v21.i27.8238. PMC 4507093. PMID 26217075.
Attar N, Kurdistani SK (March 2017). "Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer". Cold Spring Harbor Perspectives in Medicine. 7 (3): a026534. doi:10.1101/cshperspect.a026534. PMC 5334244. PMID 27881443.
Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, et al. (July 2018). "Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer". Genome Medicine. 10 (1): 54. doi:10.1186/s13073-018-0569-7. PMC 6053793. PMID 30029671.
Wang H, Xu J, Lazarovici P, Quirion R, Zheng W (2018-08-30). "cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia". Frontiers in Molecular Neuroscience. 11: 255. doi:10.3389/fnmol.2018.00255. PMC 6125665. PMID 30214393.
Steven A, Friedrich M, Jank P, Heimer N, Budczies J, Denkert C, Seliger B (October 2020). "What turns CREB on? And off? And why does it matter?". Cellular and Molecular Life Sciences. 77 (20): 4049–4067. doi:10.1007/s00018-020-03525-8. PMC 7532970. PMID 32347317.
Dyson HJ, Wright PE (March 2016). "Role of Intrinsic Protein Disorder in the Function and Interactions of the Transcriptional Coactivators CREB-binding Protein (CBP) and p300". The Journal of Biological Chemistry. 291 (13): 6714–6722. doi:10.1074/jbc.R115.692020. PMC 4807259. PMID 26851278.
Sapio L, Salzillo A, Ragone A, Illiano M, Spina A, Naviglio S (October 2020). "Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update". Cancers. 12 (11): 3166. doi:10.3390/cancers12113166. PMC 7693618. PMID 33126560.
Valor LM, Viosca J, Lopez-Atalaya JP, Barco A (2013-07-31). "Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders". Current Pharmaceutical Design. 19 (28): 5051–5064. doi:10.2174/13816128113199990382. PMC 3722569. PMID 23448461.
Dutto I, Scalera C, Prosperi E (April 2018). "CREBBP and p300 lysine acetyl transferases in the DNA damage response". Cellular and Molecular Life Sciences. 75 (8): 1325–1338. doi:10.1007/s00018-017-2717-4. PMC 11105205. PMID 29170789. S2CID 3951961.
Zhang H, Kong Q, Wang J, Jiang Y, Hua H (November 2020). "Complex roles of cAMP-PKA-CREB signaling in cancer". Experimental Hematology & Oncology. 9 (1): 32. doi:10.1186/s40164-020-00191-1. PMC 7684908. PMID 33292604.
Rubin SM, Sage J, Skotheim JM (October 2020). "Integrating Old and New Paradigms of G1/S Control". Molecular Cell. 80 (2): 183–192. doi:10.1016/j.molcel.2020.08.020. PMC 7582788. PMID 32946743.
Bodrug T, Welsh KA, Hinkle M, Emanuele MJ, Brown NG (2021-05-24). "Intricate Regulatory Mechanisms of the Anaphase-Promoting Complex/Cyclosome and Its Role in Chromatin Regulation". Frontiers in Cell and Developmental Biology. 9: 687515. doi:10.3389/fcell.2021.687515. PMC 8182066. PMID 34109183.
Van Gils J, Magdinier F, Fergelot P, Lacombe D (June 2021). "Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder". Genes. 12 (7): 968. doi:10.3390/genes12070968. PMC 8303114. PMID 34202860.
Kim C, Yousefian-Jazi A, Choi SH, Chang I, Lee J, Ryu H (November 2021). "Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease". International Journal of Molecular Sciences. 22 (22): 12499. doi:10.3390/ijms222212499. PMC 8617801. PMID 34830381.
Waddell AR, Huang H, Liao D (June 2021). "CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers". Cancers. 13 (12): 2872. doi:10.3390/cancers13122872. PMC 8229436. PMID 34201346.
Farria A, Li W, Dent SY (September 2015). "KATs in cancer: functions and therapies". Oncogene. 34 (38): 4901–4913. doi:10.1038/onc.2014.453. PMC 4530097. PMID 25659580.
Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, et al. (December 2012). "Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP". Clinical Cancer Research. 18 (24): 6623–6633. doi:10.1158/1078-0432.CCR-12-0861. PMC 3518680. PMID 22923450.

semanticscholar.org

api.semanticscholar.org

Guo P, Chen W, Li H, Li M, Li L (October 2018). "The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications". Pathology & Oncology Research. 24 (4): 807–813. doi:10.1007/s12253-018-0433-5. PMID 29948617. S2CID 47020435.
He ZX, Wei BF, Zhang X, Gong YP, Ma LY, Zhao W (January 2021). "Current development of CBP/p300 inhibitors in the last decade". European Journal of Medicinal Chemistry. 209: 112861. doi:10.1016/j.ejmech.2020.112861. ISSN 0223-5234. PMID 33045661. S2CID 222319204.
Amidfar M, de Oliveira J, Kucharska E, Budni J, Kim YK (September 2020). "The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease". Life Sciences. 257: 118020. doi:10.1016/j.lfs.2020.118020. PMID 32603820. S2CID 220287306.
Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG (April 2007). "Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis". Cell Research. 17 (4): 324–332. doi:10.1038/cr.2007.10. PMID 17372613. S2CID 36084602.
Dutto I, Scalera C, Prosperi E (April 2018). "CREBBP and p300 lysine acetyl transferases in the DNA damage response". Cellular and Molecular Life Sciences. 75 (8): 1325–1338. doi:10.1007/s00018-017-2717-4. PMC 11105205. PMID 29170789. S2CID 3951961.
Mullan PB, Quinn JE, Harkin DP (September 2006). "The role of BRCA1 in transcriptional regulation and cell cycle control". Oncogene. 25 (43): 5854–5863. doi:10.1038/sj.onc.1209872. PMID 16998500. S2CID 41157893.
Cantor AB, Orkin SH (May 2002). "Transcriptional regulation of erythropoiesis: an affair involving multiple partners". Oncogene. 21 (21): 3368–3376. doi:10.1038/sj.onc.1205326. PMID 12032775. S2CID 33364155.
Ait-Si-Ali S, Ramirez S, Barre FX, Dkhissi F, Magnaghi-Jaulin L, Girault JA, et al. (November 1998). "Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A". Nature. 396 (6707): 184–186. Bibcode:1998Natur.396..184A. doi:10.1038/24190. PMID 9823900. S2CID 4340781.
Turnell AS, Stewart GS, Grand RJ, Rookes SM, Martin A, Yamano H, et al. (December 2005). "The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression". Nature. 438 (7068): 690–695. Bibcode:2005Natur.438..690T. doi:10.1038/nature04151. PMID 16319895. S2CID 4432156.
Wang Y, Xie Q, Tan H, Liao M, Zhu S, Zheng LL, et al. (November 2021). "Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies". Pharmacological Research. 173: 105702. doi:10.1016/j.phrs.2021.105702. PMID 34102228. S2CID 235378858.
Akinsiku OE, Soremekun OS, Olotu FA, Soliman ME (2020). "Exploring the Role of Asp1116 in Selective Drug Targeting of CREBcAMP- Responsive Element-binding Protein Implicated in Prostate Cancer". Combinatorial Chemistry & High Throughput Screening. 23 (3): 178–184. doi:10.2174/1386207323666200219122057. PMID 32072894. S2CID 211193693.

worldcat.org

search.worldcat.org

He ZX, Wei BF, Zhang X, Gong YP, Ma LY, Zhao W (January 2021). "Current development of CBP/p300 inhibitors in the last decade". European Journal of Medicinal Chemistry. 209: 112861. doi:10.1016/j.ejmech.2020.112861. ISSN 0223-5234. PMID 33045661. S2CID 222319204.
Blobel GA (2000-02-01). "CREB-binding protein and p300: molecular integrators of hematopoietic transcription". Blood. 95 (3): 745–755. doi:10.1182/blood.V95.3.745.003k05_745_755. ISSN 1528-0020. PMID 10648382.